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Abstract 
Preterm pre-eclampsia (prior to 37 weeks’ gestation) remains a major cause of maternal 
and fetal morbidity and mortality particularly in low to middle income countries.  Much 
research has focused on first and second trimester predictors of pre-eclampsia with the 
aim of allowing stratification of antenatal care and trialling of potential preventative and 
therapeutic agents. However, none have been shown to be of benefit in randomised 
controlled trials.   
In this literature review we critically evaluate predictive and diagnostic tests for preterm 
pre-eclampsia and discuss their clinical use and potential value in the management of 
preterm pre-eclampsia. We defined preterm pre-eclampsia as pre-eclampsia occurring 
prior to 37 weeks’ gestation.  Substantial progress has been made in the development 
of predictive screening tests for preterm pre-eclampsia, but further research is needed 
prior to their introduction and integration into routine clinical practice. The performance 
of diagnostic tests mainly utilising angiogenic and anti-angiogenic factors for 
determining time to delivery in later pregnancy currently hold more promise than first 
trimester predictive tests, possible reflecting the heterogeneity of pre-eclampsia. 
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Introduction 
Pre-eclampsia is defined by the International Society for the Study of Hypertension in 
Pregnancy (ISSHP) as hypertension and the coexistence of one or more of the following 
new-onset conditions; proteinuria (spot urine protein/creatinine >30 mg/ mmol or >300 
mg/day or at least 1 g/L(2+) on dipstick testing); other maternal organ dysfunction 
including renal insufficiency, liver involvement, neurological complications, 
haematological complications; or evidence of uteroplacental dysfunction indicated by 
fetal growth restriction.1 For the purposes of this review, preterm pre-eclampsia is 
defined as pre-eclampsia which occurs prior to 37 weeks gestation, though we 
acknowledge the current debate regarding this binary classification 2 3. 
 
This hypertensive condition usually occurs during the second half of pregnancy, 
complicates 2% to 8% of pregnancies and remains a major cause of maternal and 
perinatal mortality and morbidity worldwide, accounting for 17-24% of all maternal 
deaths in low income settings.4 5  
Preterm pre-eclampsia is thought to arise as a result of placental ischaemia which 
arises from impaired placentation (trophoblast invasion of the maternal uterine spiral 
arteries), which in turn leads to stimulation of sustained endoplasmic reticulum and 
  
oxidative stress.6-8 This pathophysiological cascade generates the characteristic 
systemic symptoms of the maternal disease; it is affected by genetic, behavioural or 
environmental influences and is mediated by release of factors into the maternal 
circulation.9-12  In contrast, term pre-eclampsia is generally not associated with 
abnormal trophoblast invasion7 and it is thought that other maternal constitutive factors 
or the pre-existing susceptibility of the maternal vasculature is responsible for the 
development of term pre-eclampsia13.  
 
There are currently few preventative strategies and no cure other than delivery of the 
placenta; for women presenting with disease preterm, this often results in iatrogenic 
delivery to prevent serious maternal or fetal adverse outcomes.  
 
There have been wide ranging investigations into possible biomarkers for early 
identification of preterm pre-eclampsia 14. The release of factors from the placenta into 
the maternal blood stream, or maternal generation of factors may precede clinical 
symptoms 14. Therefore, there remains substantial interest in the use of these factors as 
potential biomarkers for subsequent disease. Initial research focused on angiogenic 
factors and placental-specific factors, whilst recent advances in the so called omics 
fields have led to further possible biomarkers 15 16. Table 1 summarises the biomarkers 
discussed in this review. These biomarkers, alone or in combination with biophysical 
and sonographic findings, may allow development of a reliable and valid screening or 
diagnostic test for pre-eclampsia to enable risk stratification and timely use of 
  
pharmacological interventions such as aspirin (or other novel therapies) to reduce the 
risk of pre-eclampsia.17,18 
 
A difficulty when assessing studies which look at pre-eclampsia is that many do not 
subclassify pre-eclampsia into early onset and late onset. As noted in Wu et al, this 
results in a poorly defined phenotype of pre-eclampsia which may contribute to the low 
predictive value of studies to date. 19Furthermore, as early and late onset pre-eclampsia 
are now believed to have pathogenetic mechanisms contributing in varying degrees, it is 
likely they are characterised by different biomarkers. This highlights the importance of 
stratifying by pre-eclampsia type in future studies of potential biomarkers.  
 
Many proposed tests for the short and longer-term prediction of pre-eclampsia are 
currently under investigation, and some are now being offered in clinical practice. In this 
literature review we will critically evaluate predictive and diagnostic tests for pre-
eclampsia and discuss their clinical use and potential value in the management of 
preterm pre-eclampsia. Studies are described in the text, with Table 1 providing further 
detail on statistical results.  
 
Angiogenic factors  
The placental hypoxia resulting from the impaired trophoblast invasion that occurs in 
pre-eclampsia results in an imbalance between pro- and anti-angiogenic factors, in 
particular, the anti-angiogenic soluble fms-like tyrosine kinase-1 (sFlt-1) and the pro-
angiogenic vascular endothelial growth factor (VEGF) and placental growth factor 
(PlGF).20-23 VEGF induces endothelial proliferation and vascular permeability by 
  
inducing the expression of integrins on endothelial cells that are involved in angiogenic 
invasion.24 In the placenta, it is involved not only in vascularisation, but also in 
trophoblast syncytialisation and proliferation of extravillous trophoblasts (as assessed in 
primary culture of trophoblasts and a cell line of human extravillous trophoblasts).25,26  
 
The anti-angiogenic factor sFlt-1 is a splice variant of the VEGF receptor, Flt-1 that 
lacks both the transmembrane and cytoplasmic domains of the cell membrane bound 
receptor. sFlt-1 acts as a soluble receptor that binds PlGF and also binds and 
deactivates circulating VEGF.27-30 Measurement of these angiogenic factors has 
resulted in several clinically commercially available assays.29-32  
 
Chappell and colleagues previously investigated the diagnostic accuracy of low plasma 
PlGF concentration (using the Alere Triage assay) in women presenting with suspected 
pre-eclampsia between 20 and 35 weeks' gestation (and up to 41 weeks' gestation as a 
secondary analysis). Of 287 women recruited prior to 35 weeks’ gestation, PlGF <5th 
centile had high sensitivity (96%) and negative predictive value (98%) for pre-eclampsia 
leading to delivery within 14 days; specificity was lower (55%).33  
 
For short term prediction of pre-eclampsia, a sFlt-1:PlGF ratio cut-off of 38 has been 
shown to have a negative predictive value for the development of pre-eclampsia in the 
subsequent week of 99.3% (95% CI, 97.9 to 99.9), with 80.0% sensitivity (95% CI, 51.9 
to 95.7) and 78.3% specificity (95% CI, 74.6 to 81.7). The positive predictive value of an 
sFlt-1:PlGF ratio above 38 in women between 24 weeks and 36 weeks (and 6 days) of 
  
gestation in whom pre-eclampsia was suspected, for a diagnosis of pre-eclampsia 
within four weeks was 36.7% (95% CI, 28.4 to 45.7), with 66.2% sensitivity (95% CI, 
54.0 to 77.0) and 83.1% specificity (95% CI, 79.4 to 86.3).32 A separate study 
demonstrated that PlGF (ROC 0.87, 95% CI 0.83–0.92), sFlt-1 (ROC 0.83, 95% CI 
0.78–0.88) and endoglin (ROC 0.83, 95% CI 0.79–0.88) all have comparable results in 
the short term prediction for pre-eclampsia requiring delivery within 14 days in women 
with suspected preterm pre-eclampsia.34  
 
Whilst the use of these tests for diagnosis is promising, predictive studies have had 
more mixed results. A prospective international multicentre study recruited 5121 
participants between 2006 and 2009 who had risk factors for pre-eclampsia (nulliparity, 
diabetes, previous pre-eclampsia or chronic hypertension). Participants had their serum 
tested for sFlt-1, PlGF and endoglin concentrations and urine PlGF measured at fixed 
time-points of ≤20, 23-27 and 32-35 weeks' gestation. Of this cohort, 3.9% (198 women) 
developed pre-eclampsia, with 0.9% (47 women) developing pre-term pre-eclampsia. 
The median maternal serum concentrations of PlGF, sFlt-1, sFlt-1/PlGF and endoglin 
were significantly different in women who subsequently developed pre-eclampsia 
compared with those who did not. However, the areas under receiver operating 
characteristics curves at ≤20 weeks' gestation were poor for predicting any pre-
eclampsia (0.52 and 0.59) or pre-eclampsia at less than 34 weeks' gestation (0.50 to 
0.63)). The corresponding sensitivity, specificity and likelihood ratios were also poor.35  
 
  
A further recent longitudinal prospective cohort observational study of angiogenic 
markers and Angiotensin II type 1 receptor antibodies (AT1AA) was conducted. In pre-
eclampsia there is an enhanced vascular sensitivity to angiotensin II and norepinephrine 
resulting in vasoconstriction and hypertension. The enhanced sensitivity to angiotensin 
II may be secondary to increased bradykinin upregulation seen in preeclamptic patients. 
Hence it has been proposed as a potential biomarker.36 Sequential recruitment of 351 
women with a singleton pregnancy was undertaken. Plasma concentrations of women 
with a singleton pregnancy at 12, 18, 28, 36, 40 weeks’ gestation and 6 weeks post-
partum were assessed for levels of AT1AA, PlGF, sFlt-1 and endoglin. Women with pre-
eclampsia had higher sFlt-1 from 28 weeks onwards (p= 0.003) and lower PlGF from 18 
weeks (p=0.004). Endoglin and AT1AA concentrations did not vary over time or 
between groups.37 PlGF compares favourably when used as a first trimester screening 
tool as evidenced by a recent systematic review which included a total of 103 studies 
and 432,621 participants. This reviewed the accuracy of serum biochemical markers 
PAPP-A, human Chorionic Gonadotropin, PlGF and Placental Protein 13 (PP13) in the 
first trimester to predict pre-eclampsia.38 For pre-eclampsia, the best predictor was PlGF 
with a positive likelihood ratio of 4.01 (3.74, 4.28) and a negative likelihood ratio of 0.67 
(0.64, 0.69).  
  
 
 
Endothelial dysfunction  
Endothelial cells are important in the systemic inflammatory response as well as 
mediating local inflammation by upregulating the secretion of cytokines and adhesion 
molecules such as intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion 
molecule 1 (VCAM-1) and E-selectin. Plasma concentrations of these adhesion cell 
molecules are significantly elevated in women with pre-eclampsia.42-44 Elevations in 
these molecules have been demonstrated before clinical symptoms develop, suggesting 
they may serve as predictors of pre-eclampsia. One prospective study of samples from 
57 pregnant women before and after 32 weeks’ gestation demonstrated that VCAM-1 
was significantly elevated in women developing hypertensive diseases as compared to 
normotensive women (pre-eclampsia: p<0.001; gestational hypertension: p<0.05; 
chronic hypertension: p<0.001).  
 
Cell free fetal DNA 
Cell free fetal DNA (cffDNA) refers to fetal DNA found in the maternal blood stream. 
This is now a minimally- invasive technique increasingly being used to screen for 
genetic anomalies. It has also been proposed as a biomarker for pre-eclampsia. A 
systematic review examined 13 studies of which 11 had found an increase in cffDNA 
among pregnant women who subsequently developed pre-eclampsia. In addition, all 
four studies examining early-onset or severe pre-eclampsia found significantly elevated 
  
cffDNA levels prior to disease onset.45 Additional recent case control studies examining 
first trimester cffDNA showed no association with first trimester cffDNA and subsequent 
development of pre-eclampsia.46 However, these data conflict with a larger case control 
study supporting an association. In this study, compared with controls, the median 
levels and multiples of the median (MoM) values of HYP2, a cell free fetal DNA marker, 
were significantly higher in the pre-eclampsia and hypertensive disorders of pregnancy 
groups sampled at 6-14 and 15-23 weeks’ gestation.47 HYP2 is located on chromosome 
13 and is hypermethylated in the placenta as well as in maternal blood cells. It has been 
studied as an epigenetic marker for total cffDNA 48. 
 
Levine et al conducted a nested case control study within the Calcium for Pre-eclampsia 
Prevention trial cohort of healthy nulliparous women. One hundred twenty pairs were 
randomly chosen for analysis of serum cell-free fetal DNA (cffDNA), a marker of 
placental debris, and C-reactive protein (CRP), a marker of inflammation. Serum 
specimens were obtained from participants at 8 to 20 weeks (at enrolment in the trial), 
at 26 to 29 weeks, at 36 weeks if still pregnant, and when hypertension or proteinuria 
were noted and a diagnosis of pre-eclampsia confirmed. At 29 to 41 weeks of gestation, 
cffDNA concentrations were significantly higher after a diagnosis of pre-eclampsia was 
made than before (219 vs 112 genome equivalents [GE]/mL, P<.001). Before the 
diagnosis of pre-eclampsia was made, cffDNA levels in cases exceeded controls at 17 
to 28 weeks (36 vs 16 GE/mL, P<.001). However, samples taken between 29 and 41 
weeks were only significantly elevated within 3 weeks prior to the diagnosis of pre-
eclampsia (176 vs 75 GE/mL, P<.001).49 These data suggest that cffDNA may be useful 
  
in the both early and late stage detection of preterm pre-eclampsia, as pre-eclampsia 
appears to be accompanied by a 2-stage elevation of fetal DNA.  
Cotter et al reanalysed blood samples from women attending first antenatal clinics 
which were stored in a biobank. 88 women who subsequently developed pre-eclampsia 
(cases) and 176 matched controls were sampled at a mean gestation (+/-SD) of 15.7 +/- 
3.6 weeks. The presence of fetal DNA in the maternal circulation in early pregnancy 
was associated with an 8-fold increased risk of developing pre-eclampsia.50 This study 
did not differentiate between preterm and term pre-eclampsia.  
Cell free RNA has also been proposed as a marker for pre-eclampsia. One study 
examined maternal plasma samples from 62 patients at a tertiary hospital in Indonesia 
from 15-20 weeks gestation who subsequently developed either early or late onset pre-
eclampsia. These were compared with samples from 310 controls (unmatched subjects 
with a normal pregnancy) using a panel of messenger RNA markers. A receiver 
operating characteristic curve that was obtained with the estimated score for pre-
eclampsia as a test variable yielded a detection rate of 84% (95% CI, 71.8-91.5) at a 
5% false-positive rate with an area under the curve of 0.927 (P <0 .001).51  
 
Immunological response, oxidative stress and inflammation 
In pre-eclampsia, the systemic inflammatory response reported in uncomplicated 
normal pregnancies52 becomes exaggerated resulting in abnormal activation of 
monocytes, platelets and the endothelium.53 In addition, many acute phase 
inflammatory proteins increase including C-reactive protein, angiotensinogen, alpha-1-
  
acid glycoprotein, alpha-1-antitrypsin, caeruloplasmin and fibrinogen. Moreover, as part 
of the inflammatory response, microparticles (plasma membrane-derived vesicles) are 
released and elevated levels of circulating microparticles have been shown to correlate 
with the endothelial dysfunction documented in pre-eclampsia.54,55 
 
During placentation, Natural Killer (NK) cells play an important role in the decidual 
inflammatory response. Decidual NK cells, which are a specialised subset of NK cells, 
are present pre-conceptually in the endometrium of the luteal phase56. Decidual 
inflammation contributes to the shallow placentation in pre-eclampsia by promoting 
excess decidual cell IP-10 (IFN-γ–induced protein 10), a chemokine. This has been 
shown to be elevated in the first trimester in a study of 90 women who subsequently 
developed pre-eclampsia.57    
 
Oxidative stress is defined as an increase in the steady state levels of reactive oxygen 
species (ROS) and may occur as a result of increased free radical generation and/or 
reduced antioxidant activity. In pre-eclampsia there is an increase in the levels of 
placental oxidative stress and this oxidative stress may mediate endothelial cell 
dysfunction and contribute to the pathophysiology of pre-eclampsia.58 In pre-eclampsia, 
oxidative stress may result from interactions between the maternal component 
(including pre-existing conditions such as obesity, diabetes, and hyperlipidemia) and/or 
the placental component that may involve secretion of lipid peroxides.59 In a prospective 
observational study of 306 nulliparous women, markers of oxidative stress including 
cholesterol and caeruloplasmin levels taken at 14-16 weeks’ gestation (sample 1) and 
  
at 18-20 weeks (sample 2) were shown to correlate with the development of pre-
eclampsia.60 
 
Metabolomics and proteomics 
Metabolomics, the scientific study of chemical processes involving metabolites, the 
intermediates and products of metabolism, has more recently been applied in the 
prediction of pre-eclampsia. Current metabolomic technologies have allowed the 
establishment of metabolic signatures of pre-eclampsia in early pregnancy. A two-phase 
discovery/validation metabolic profiling study from samples taken at 15 weeks’ gestation 
demonstrated an odds ratio for developing pre-eclampsia of 36 (95% CI: 12 to 108), 
with an area under the receiver operator characteristic curve of 0.94 using a multivariate 
predictive model combining 14 metabolites.61 
 
These findings were then validated using plasma obtained at 15 weeks’ gestation from 
39 women who subsequently developed pre-eclampsia and 40 similarly matched 
controls. In an independent case-control study the same 14 metabolites produced an 
odds ratio of 23 (95% CI: 7 to 73) with an area under receiver operator characteristic 
curve of 0.92. A phase IIa clinical study of predictive testing for pre-eclampsia to 
evaluate whether this leads to improved pregnancy outcomes through earlier detection 
is currently recruiting using this metabolomic platform.16 The 14 metabolites included in 
this model were 5-Hydroxytryptophan, Monosaccharide(s), Decanoylcarnitine,  
Methylglutaric acid and/or adipic acid, Oleic acid, Docosahexaenoic acid and/or 
docosatriynoic acid, γ-Butyrolactone and/or oxolan-3-one, 2-Oxovaleric acid and/or oxo-
  
methylbutanoic acid, Acetoacetic acid, Hexadecenoyl-eicosatetraenoyl-sn-glycerol, Di-
(octadecadienoyl)-sn-glycerol, Sphingosine 1-phosphate, Sphinganine 1-phosphate and 
Vitamin D3 derivatives. 
 
Myers et al conducted a proteomics pipeline study which reported 8 validated models 
that predicted 50-56% cases of pre-eclampsia, centred on insulin like growth factor acid 
labile subunit 15. A recent study suggested an association between predisposition to 
pre-eclampsia and cardiovascular disease, suggesting that this field may contribute to 
risk stratification of pregnant women for long term morbidities 62. Pregnancy specific 
glycoproteins have also been investigated as potential predictors of early-onset pre-
eclampsia.63  
 
Placental-derived and other proteins 
Other biomarkers proposed for pre-eclampsia include disintegrin and metalloprotease 
12 (ADAM-12), inhibin-A and activin-A, pregnancy associated plasma protein A (PAPP-
A) and placental protein 13 (PP-13).64 PP-13 is a galectin that binds to proteins on the 
extracellular matrix between the placenta and the endometrium, and through its action 
as a lysophospholipase-A assists in placental implantation and maternal artery 
remodelling. PP-13 appears to be down-regulated in women with pre-eclampsia 
requiring early delivery.65 A nested case control study of 446 controls and 44 cases who 
subsequently developed preterm pre-eclampsia (delivery prior to 35 weeks) yielded 
areas under the receiver operating characteristics curve for first trimester PP-13, PAPP-
A and second trimester uterine artery pulsatility index respectively of 0.71 (95% CI, 
  
0.63–0.79; P < 0.001), 0.59 (95% CI, 0.51–0.68; P = 0.076) and 0.86 (95% CI, 0.77–
0.94; P < 0.001). Combining PP-13 and pulsatility index using logistic regression 
analysis yielded an area under the curve of 0.90 (95% CI, 0.84–0.96; P < 0.001) and a 
sensitivity of 0.79.66 In one prospective study of early pregnancy activin A and inhibin A 
were significantly higher in preeclamptic patients than in the other groups (activin A: 
normotension: p<0.005; gestational hypertension: p<0.001; chronic hypertension: 
p<0.005) (inhibin A: normotension: p<0.005; gestational hypertension: p<0.001; chronic 
hypertension: p<0.01)67 but these changes have not translated into a clinically 
applicable predictive or diagnostic test.  
 
 
Misfolded proteins 
Endoplasmic reticulum stress in the placenta, as in other cell types, leads to 
upregulation of the unfolded protein response pathway.68-70 The unfolded protein 
response is a common cellular defence mechanism that promotes removal of unfolded 
or misfolded proteins to prevent potentially toxic accumulation. Buhimschi and 
colleagues recently proposed that the presence of elevated urine congophilia (which is 
thought to indicate the presence of amyloid protein, an aggregate of misfolded proteins) 
assessed using the Congo red ‘dot’ test was useful in the diagnosis of pre-eclampsia 
and the prediction of medically indicated delivery. In a prospective cohort study (n = 
563) they demonstrated that Congo red retention (CRR) using a cut-off of ≥15% had a 
sensitivity of 85.9% (95% CI, 81.1 to 89.9), specificity of 85.0% (95% CI, 80.4 to 88.8), 
positive likelihood ratio of 5.7 (95% CI, 4.4 to 7.5), and negative likelihood ratio of 0.17 
  
(95% CI, 0.1 to 0.2) in predicting pre-eclampsia requiring medically indicated delivery. 
The association of Congo red retention with medically indicated delivery remained 
significant after controlling for gestational age and maternal demographic characteristics 
in multiple logistic regression. Women with pre-eclampsia were sampled at a median of 
34-36 weeks’ gestation in this cohort.71,72 However, a more recent study demonstrated 
that in addition to women with pre-eclampsia, women with chronic kidney disease 
without pre-eclampsia have elevated urine Congo Red retention compared to healthy 
pregnant women. Non-pregnant women with lupus nephritis also had elevated urine 
congophilia compared with healthy controls demonstrating that an elevated Congo Red 
retention may not be able to differentiate between these conditions.73 
 
Combined screening 
A recent systematic review and meta-analysis demonstrated the pooled sensitivity of all 
single biomarkers to be 0.40  at a false positive rate of 10%. The area under the 
Summary of Receiver Operating Characteristics Curve (SROC) was 0.786 . When a 
combination model was used, the predictive value improved to an area under the SROC 
of 0.893 .19 A combination of biophysical, biochemical and ultrasound markers may 
provide a more useful screening test than a test of either component alone. 
 
Screening by maternal characteristics and medical history alone identifies 
approximately 35% of all cases of pre-eclampsia and about 40% of pre-term pre-
eclampsia cases, at a false-positive rate of 10%.74 First trimester screening by maternal 
factors with biochemical (PAPP-A and B-hCG) and biophysical markers (blood pressure 
  
and uterine artery Doppler) yields detection rates of all pre-eclampsia and pre-
eclampsia requiring delivery before 37 and 34 weeks’ gestation of 54%, 75% and 88%, 
respectively, at a false-positive rate of 10%.75,76  
 
The Screening for Pregnancy Endpoints (SCOPE) study developed a predictive model 
that utilised clinical risk factors and putative biomarkers to predict pre-eclampsia in low 
risk nulliparous women 30. A cohort of 5628 women was used to develop and validate a 
model to predict early onset pre-eclampsia, which included placental growth factor, 
mean arterial pressure, BMI at 14 to 16 weeks’ gestation, the consumption of ≥3 pieces 
of fruit per day and mean uterine artery resistance index. The area under the ROC for 
this model in training and validation cohorts was 0.73 and 0.68 respectively, a modest 
prediction at best. This study concluded the model did not perform at a level acceptable 
for introduction to clinical practice, and that due to the low prevalence of pre-eclampsia, 
the test resulted in an unacceptable number of false-positive rates.    
 
More recently, an analysis of a prospective cohort study of 35,948 women attending for 
their routine first hospital visit at 11-13 weeks gestation at two maternity hospitals in 
England was undertaken. . This cohort included 1058 pregnancies with pre-eclampsia 
(2.9%) demonstrated that prospective combined screening by maternal factors, uterine 
artery pulsatility index, mean arterial pressure, and placental growth factor predicted 
75% (95% confidence interval, 70-80%) of preterm-pre-eclampsia and 47% (95% 
confidence interval, 44-51%) of term-pre-eclampsia, at a false-positive rate of 10%.77  
 
  
Conclusion 
Substantial progress in research has been made in recent years, which has 
considerably improved our understanding of the aetiology of pre-eclampsia. Findings 
from initial case-control studies require validation in prospective cohort studies and 
robust evaluation through randomised controlled trials (of a predictive or diagnostic test) 
before routine introduction into clinical practice. Increasingly, robust clinical studies are 
being performed assessing a variety of tools for the first and second trimester prediction 
of pre-eclampsia and point of care tests for assessing need for delivery. Measurement 
of angiogenic and anti-angiogenic factors remains the leading commercially available 
test to aid in the short-term diagnosis of pre-eclampsia requiring need for delivery within 
two weeks. Ongoing clinical trials will provide robust data on the clinical potential for first 
and second trimester prediction of pre-eclampsia.  
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Table 1. Selected biomarkers and their clinical efficacy 
 Clinical 
cutoff 
Primary outcome Sensitivit
y (95% 
CI) 
Specificit
y (95% 
CI) 
OR   
(95% 
CI) 
ROC 
(95% CI) 
+ LR 
(95% 
CI) 
- LR 
(95% 
CI) 
P 
value 
Angiogenic 
markers 
         
PIGF 
32
 <5th 
centile 
Any PE 
diagnosis at 20-
35/40 gestation 
0.96 
(0.89-
0.99) 
0.55(0.48
-0.61) 
   0.98 
(0.93-
1.00) 
 
sFlt-1 : PIGF 
ratio 
31
 
Ratio>38 Prediction of PE 
in next 7 days 
0.80 
(0.52-
0.96) 
0.78 
(0.75- 
0.82) 
   0.99 
(0.98-
1.00) 
 
sFlt-1, endoglin 
33
 
 Prediction of 
preterm PE 
requiring 
delivery<14 days 
   0.83 
(0.78–
0.88) 
0.83 
(0.79–
0.88) 
   
PIGF, sFlt, 
sFLT-1:PIGF, 
endoglin 
34
 
Combined 
predictor 
Prediction of PE 
at <20/40 and 
<34/40 gestation 
   (0.52-
0.59) 
(0.50-
0.63) 
   
Endothelial 
dysfunction 
         
  
VCAM-1 
44
 Mean 
concentrati
on 
Comparison of 
women with 
hypertensive 
diseases to 
normotensive 
women, >32/40 
      <0.00
1 
Cell free fetal 
DNA 
48
 
Mean 
concentrati
on 
Nested case 
control of women 
with PE, cffDNA 
concentrations at 
29-41/40 
      <0.00
1 
Cell free RNA 
50
 
Panel of 
mRNA 
markers, 
FPR 10% 
Case control of 
women who 
developed early 
or late onset PE 
   0.93 
DR 84 
(71.8-
91.5) 
  <0.00
1 
Metabolomics          
14 metabolites* 
60
 
Predictive 
model 
Discovery study, 
15/40 gestation 
  36 (12-
108) 
0.94    
14 metabolites* 
60
 
Predictive 
model 
Validation study, 
15/40 gestation, 
case control 
  23 (7-
73) 
0.92    
Placental 
derived 
proteins 
         
PAPP-A 
65
 Mean 
concentrati
on 
Nested case 
control, cases 
delivered<35/40 
due to PE 
.   0.59 
(0.51–
0.68) 
  0.076 
PP-13 + UA 
pulsatility index 
65
 
Combined 
predictor 
Nested case 
control, cases 
delivered<35/40 
due to PE 
0.79   0.90 
(0.84–
0.96) 
  <0.00
1 
Misfolded 
proteins 
  .       
Urine 
congophilia 
71
 
Congo red 
retention 
>15% 
Prediction of PE 
requiring 
medically 
indicated 
delivery, 
sampled at 34-
36/40 
85.9 
(81.1 - 
89.9) 
   5.7 
(4.4-
7.5) 
0.17 
(0.1-
0.2) 
 
Combined 
screening 
  . .      
Combined 
screening
+ 77
 
FPR of 
10% 
 
Preterm PE; 
Term PE,  
75.0 
(70.0-
80.0);  
47.0 
(44.0-
51.0) 
.      
Combined 
screening 
$ 29
  
 Prediction of PE 
in low risk 
nulliparous 
women 
. .  0.68 
(0.63-
0.74) 
   
OR odds ratio; + LR positive likelihood ratio; - LR negative likelihood ratio; ROC area under the receiver operating characteristic 
curve; DR detection rate; PE: pre-eclampsia; *5-Hydroxytryptophan, Monosaccharide(s), Decanoylcarnitine,  Methylglutaric acid 
and/or adipic acid, Oleic acid, Docosahexaenoic acid and/or docosatriynoic acid, γ-Butyrolactone and/or oxolan-3-one, 2-Oxovaleric 
acid and/or oxo-methylbutanoic acid, Acetoacetic acid, Hexadecenoyl-eicosatetraenoyl-sn-glycerol, Di-(octadecadienoyl)-sn-
glycerol, Sphingosine 1-phosphate, Sphinganine 1-phosphate and Vitamin D3 derivatives; 
+ 
maternal factors, uterine artery 
pulsatility index, mean arterial pressure, and placental growth factor; 
$ 
placental growth factor, mean arterial pressure, BMI at 14 to 
16 weeks’ gestation, the consumption of ≥3 pieces of fruit per day and mean uterine artery resistance index 
 
  
  
 
Highlights 
 Preterm preeclampsia remains an important condition associated with substantial 
maternal and fetal morbidity and mortality, particularly in the developing world. 
 Preeclampsia is thought to occur as a result of a two stage process: impaired 
trophoblast invasion resulting in placental ischemia, coupled and interacting with 
maternal constitutional factors including genetic, behavioural and environmental 
influences.   
 Conflicting evidence exists regarding aetiology and potential biomarkers, which 
likely reflects the heterogeneity of the condition and the historical grouping of 
term and preterm preeclampsia in studies. 
 The development of tests to date has focused on first or second trimester 
screening, and diagnostic tests to aid in the prediction of time to delivery. 
 Placental growth factor and soluble fms-like tyrosine kinase-1 have provided the 
most promising results as a test to assist in determining need to delivery within a 
short time-frame. 
 Placental growth factor in combination with clinical parameters is also useful in 
the first trimester prediction of preeclampsia; however, larger robust clinical trials 
are required. 
 A phase IIa clinical study is currently being performed using a metabolomic 
platform. Robust clinical studies similar to this are required to examine other 
biomarkers.   
  
 There is a need to address the translational gap between biomarkers which have 
shown promising results and the introduction using clinical trials into clinical 
practice.  
 
